“It’s one thing for us to get the biosimilar approved and go through all of that,” said Juliana M. Reed, corporate affairs global biosimilars lead for Pfizer. “That was the early conversation of the market developing. Now the market needs to be accessible.”
So far, 2018 has been a notable for Pfizer’s biosimilar ambitions, with the FDA having approved 2 supportive care biosimilars—a filgrastim and an epoetin alfa—already this year, bringing the company’s total number of US-licensed biosimilars to 4.
In an interview with The Center for Biosimilars®, John P. Kennedy, general manager of US Biosimilars for Pfizer Essential Health, said of these new approvals, “We’re excited that we are building a robust portfolio that is in line with our intent, which is to be a significant and leading player in the biosimilars space more broadly.”
But while Pfizer has been making strides forward on the regulatory front, uptake of its 1 commercially launched US biosimilar, Inflectra, has remained disappointingly low, even though Inflectra’s average sales price (ASP)—$602.30 for 100 mg—is currently 24% lower than Remicade’s ASP of $792.50 for 100 mg, according to data provided by Pfizer.
Despite the potential savings posed by the lower-price biosimilar, according to data from Avalere, just 2% of patients with commercial coverage can freely access Inflectra as the first step in their biologic therapy. And while a recent case study from The Pacific Research Institute indicated that if biosimilars of infliximab were to reach 50% market annual cost reductions for patients with employer-based coverage could be as high as 8.4%, and for patients covered by Medicare, as high as 8.1%, uptake remains slow.
Kennedy said that while the company is “seeing some traction in the Medicare space, where value is more appreciated,” and is “making inroads in terms of increased coverage among some commercial payers,” challenges linger for Inflectra in the face of what it has called anticompetitive conduct on the part of Remicade’s sponsor, Johnson & Johnson (J&J).
In 2017, Pfizer filed a lawsuit against J&J, saying that the company threatened to withhold rebates from insurers unless they agreed to exclude biosimilars from their formularies. The case is currently awaiting a ruling, and, according to Pfizer, very little has changed in the market during the intervening year.
Juliana M. Reed, corporate affairs global biosimilars lead for Pfizer, added that, as evidenced by the FDA’s newly unveiled Biosimilar Action Plan, “There’s a growing sense of concern with the administration that the barriers that are in front of biosimilar uptake will continue and that the market won’t form or be substantial. J&J's exclusionary contracts are definitely part of that.”
To Reed, the FDA’s plan represents an encouraging step forward; while she noted that Pfizer looks forward to the emergence of further detail, she feels that the document addresses most of the items on which the company has been awaiting greater clarity.
Reed also sees the FDA’s signals that it intends to partner more closely with the Federal Trade Commission (FTC) on addressing anticompetitive behavior as a positive. “It’s one thing for us to get the biosimilar approved and go through all of that,” she said. “That was the early conversation of the market developing. Now the market needs to be accessible.”
Greater regulatory alignment with the FTC has the potential to provide for just that, according to Reed, by addressing anticompetitive practices in a variety of forms, including addressing misinformation—or what Reed termed “fear-mongering”—about biosimilar safety; while the FDA can provide education about biosimilars, the FTC may have the authority to address inaccurate materials in the public space that have a chilling impact on competition.
Those steps forward could provide a key to ensuring the future of the biosimilars market in the United States. According to Pfizer, if behavior in the market does not change, neither will patterns of uptake and cost savings.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.